Davide Sparasci, Lenka Schilg-Hafer, Bettina Schreiner, Olivier Scheidegger, Anne-Kathrin Peyer, Agustina Maria Lascano, Alex Vicino, Bernhard Friedrich Décard, Pinelopi Tsouni, Andrea Monika Humm, Enea Pianezzi, Giulia Zezza, Thomas Hundsberger, Anelia Dietmann, Hans H. Jung, Thierry Kuntzer, Einar Wilder-Smith, Gladys Martinetti-Lucchini, Orlando Petrini, Stefano Fontana, Peter Gowland, Christoph Niederhauser, Claudio Gobbi, Paolo Ripellino
{"title":"神经性肌萎缩前的免疫诱因","authors":"Davide Sparasci, Lenka Schilg-Hafer, Bettina Schreiner, Olivier Scheidegger, Anne-Kathrin Peyer, Agustina Maria Lascano, Alex Vicino, Bernhard Friedrich Décard, Pinelopi Tsouni, Andrea Monika Humm, Enea Pianezzi, Giulia Zezza, Thomas Hundsberger, Anelia Dietmann, Hans H. Jung, Thierry Kuntzer, Einar Wilder-Smith, Gladys Martinetti-Lucchini, Orlando Petrini, Stefano Fontana, Peter Gowland, Christoph Niederhauser, Claudio Gobbi, Paolo Ripellino","doi":"10.1111/ene.16462","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background and purpose</h3>\n \n <p>Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This was a multicentre, prospective, observational, matched case–control study. NA was diagnosed by neuromuscular experts according to validated clinical criteria and electrodiagnostic studies. Clinical data and biological samples of NA patients were collected within 90 days from disease onset between June 2018 and December 2023. All NA patients were asked about prior infection and vaccination in the month before disease onset. Serological tests for hepatitis E virus, human immunodeficiency virus, severe acute respiratory syndrome coronavirus 2, Epstein–Barr virus, cytomegalovirus, parvovirus B19, varicella-zoster virus, <i>Borrelia burgdorferi</i>, <i>Mycoplasma pneumoniae</i> and <i>Bartonella henselae</i> were performed in a central laboratory. Each case was matched with a healthy control for age, sex, place of residence and time of blood collection.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifty-seven patients and corresponding controls were included. The mean age was 45 years for both groups. NA onset was preceded by a symptomatic infectious trigger confirmed by microbiological tests in 15/57 (26.3%) patients. Coronavirus disease 2019 vaccination was considered a potential trigger in 7/57 (12.3%) subjects. An acute viral infection was associated with a bilateral involvement of the brachial plexus (<i>p</i> = 0.003, Cramèr's <i>V</i> = 0.43).</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Confirmed immune triggers (infection or vaccination) preceded disease onset in 22/57 (38.6%) NA cases. We suggest to test NA patients in the acute phase for intracellular antigens, especially in the case of concomitant bilateral involvement and hepatitis.</p>\n </section>\n </div>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"31 12","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554871/pdf/","citationCount":"0","resultStr":"{\"title\":\"Immune triggers preceding neuralgic amyotrophy\",\"authors\":\"Davide Sparasci, Lenka Schilg-Hafer, Bettina Schreiner, Olivier Scheidegger, Anne-Kathrin Peyer, Agustina Maria Lascano, Alex Vicino, Bernhard Friedrich Décard, Pinelopi Tsouni, Andrea Monika Humm, Enea Pianezzi, Giulia Zezza, Thomas Hundsberger, Anelia Dietmann, Hans H. Jung, Thierry Kuntzer, Einar Wilder-Smith, Gladys Martinetti-Lucchini, Orlando Petrini, Stefano Fontana, Peter Gowland, Christoph Niederhauser, Claudio Gobbi, Paolo Ripellino\",\"doi\":\"10.1111/ene.16462\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background and purpose</h3>\\n \\n <p>Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Methods</h3>\\n \\n <p>This was a multicentre, prospective, observational, matched case–control study. NA was diagnosed by neuromuscular experts according to validated clinical criteria and electrodiagnostic studies. Clinical data and biological samples of NA patients were collected within 90 days from disease onset between June 2018 and December 2023. All NA patients were asked about prior infection and vaccination in the month before disease onset. Serological tests for hepatitis E virus, human immunodeficiency virus, severe acute respiratory syndrome coronavirus 2, Epstein–Barr virus, cytomegalovirus, parvovirus B19, varicella-zoster virus, <i>Borrelia burgdorferi</i>, <i>Mycoplasma pneumoniae</i> and <i>Bartonella henselae</i> were performed in a central laboratory. Each case was matched with a healthy control for age, sex, place of residence and time of blood collection.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>Fifty-seven patients and corresponding controls were included. The mean age was 45 years for both groups. NA onset was preceded by a symptomatic infectious trigger confirmed by microbiological tests in 15/57 (26.3%) patients. Coronavirus disease 2019 vaccination was considered a potential trigger in 7/57 (12.3%) subjects. An acute viral infection was associated with a bilateral involvement of the brachial plexus (<i>p</i> = 0.003, Cramèr's <i>V</i> = 0.43).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusions</h3>\\n \\n <p>Confirmed immune triggers (infection or vaccination) preceded disease onset in 22/57 (38.6%) NA cases. We suggest to test NA patients in the acute phase for intracellular antigens, especially in the case of concomitant bilateral involvement and hepatitis.</p>\\n </section>\\n </div>\",\"PeriodicalId\":11954,\"journal\":{\"name\":\"European Journal of Neurology\",\"volume\":\"31 12\",\"pages\":\"\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2024-10-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11554871/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Neurology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1111/ene.16462\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.16462","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
摘要
背景和目的:感染和疫苗接种被认为是神经性肌营养不良症(NA)的潜在免疫诱因,但前者的确切类型和频率尚不清楚:这是一项多中心、前瞻性、观察性、匹配病例对照研究。NA由神经肌肉专家根据有效的临床标准和电诊断学研究进行诊断。在2018年6月至2023年12月期间,收集了NA患者发病后90天内的临床数据和生物样本。所有NA患者均被问及发病前一个月的既往感染和疫苗接种情况。在中心实验室进行了戊型肝炎病毒、人类免疫缺陷病毒、严重急性呼吸系统综合征冠状病毒 2、爱泼斯坦-巴氏病毒、巨细胞病毒、B19 副病毒、水痘-带状疱疹病毒、布氏波氏杆菌、肺炎支原体和鸡巴顿氏菌的血清学检测。每个病例都与健康对照组进行了年龄、性别、居住地和采血时间的匹配:结果:共纳入 57 名患者和相应的对照组。两组患者的平均年龄均为 45 岁。15/57(26.3%)名患者在NA发病前曾有过经微生物检测证实的无症状感染诱因。7/57(12.3%)名受试者认为 2019 年接种的冠状病毒疾病是潜在的诱因。急性病毒感染与双侧臂丛神经受累有关(p = 0.003,Cramèr's V = 0.43):在 22/57 例(38.6%)NA 患者中,经证实的免疫诱因(感染或接种疫苗)发生在发病之前。我们建议对急性期的 NA 患者进行细胞内抗原检测,尤其是在同时伴有双侧受累和肝炎的情况下。
Infections and vaccinations have been identified as potential immunological triggers of neuralgic amyotrophy (NA), but the exact type and frequency of the preceding agents is unknown.
Methods
This was a multicentre, prospective, observational, matched case–control study. NA was diagnosed by neuromuscular experts according to validated clinical criteria and electrodiagnostic studies. Clinical data and biological samples of NA patients were collected within 90 days from disease onset between June 2018 and December 2023. All NA patients were asked about prior infection and vaccination in the month before disease onset. Serological tests for hepatitis E virus, human immunodeficiency virus, severe acute respiratory syndrome coronavirus 2, Epstein–Barr virus, cytomegalovirus, parvovirus B19, varicella-zoster virus, Borrelia burgdorferi, Mycoplasma pneumoniae and Bartonella henselae were performed in a central laboratory. Each case was matched with a healthy control for age, sex, place of residence and time of blood collection.
Results
Fifty-seven patients and corresponding controls were included. The mean age was 45 years for both groups. NA onset was preceded by a symptomatic infectious trigger confirmed by microbiological tests in 15/57 (26.3%) patients. Coronavirus disease 2019 vaccination was considered a potential trigger in 7/57 (12.3%) subjects. An acute viral infection was associated with a bilateral involvement of the brachial plexus (p = 0.003, Cramèr's V = 0.43).
Conclusions
Confirmed immune triggers (infection or vaccination) preceded disease onset in 22/57 (38.6%) NA cases. We suggest to test NA patients in the acute phase for intracellular antigens, especially in the case of concomitant bilateral involvement and hepatitis.
期刊介绍:
The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).